{
    "clinical_study": {
        "@rank": "104005", 
        "arm_group": {
            "arm_group_label": "Triptorelin embonate 22.5 mg", 
            "arm_group_type": "Experimental", 
            "description": "Two consecutive injections of triptorelin pamoate 22.5 mg at an interval of 24 weeks"
        }, 
        "brief_summary": {
            "textblock": "The study will investigate the efficacy, pharmacokinetics and safety of triptorelin embonate\n      22.5 mg 6-month formulation administered by subcutaneous injections in patients with\n      prostate cancer"
        }, 
        "brief_title": "Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The study will investigate the efficacy, pharmacokinetics and safety of two subcutaneous\n      injections of triptorelin embonate 22.5 mg 6-month formulation in patients with prostate\n      cancer. The total duration of the study per patient will be 12 months (48 weeks)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically proven prostate cancer.\n\n          -  Prostate cancer stage T3-4NxMx, TxN1Mx or TxNxM1 according to the TNM classification\n             (see Appendix A: TNM Classification) or the patient should have rising PSA after\n             failed local therapy and be candidate for androgen deprivation therapy.\n\n          -  Serum testosterone levels > 5 nmol/L.\n\n          -  Karnofsky performance index > 40 (see Appendix B: Karnofsky Performance Scale).\n\n          -  Expected survival > 18 months.\n\n          -  Absence of another malignancy, other than local dermatological, for the previous 5\n             years.\n\n          -  Signed informed consent before entry into the study.\n\n        Exclusion Criteria:\n\n          -  Prior hormonal treatment for prostate cancer within 6 months prior to study start.\n\n          -  Use of finasteride (Proscar\u00ae) or dutasteride (Avodart\u00ae/Avolve\u00ae) within 2 months prior\n             to study start.\n\n          -  Presence of another neoplastic lesion or brain metastases.\n\n          -  Prior hypophysectomy or adrenalectomy.\n\n          -  Known or suspicion of vertebral metastases with risk of spinal compression.\n\n          -  Severe kidney or liver failure (creatinine > 2 x upper limit of normal (ULN),\n             aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) > 3 x ULN).\n\n          -  Any concomitant disorder or resulting therapy that is likely to interfere with\n             patient compliance or with the study in the opinion of the Investigator.\n\n          -  Participation in another study with an experimental drug within 3 months before study\n             start or within 5 drug half-lives of the investigational drug (whichever is the\n             longer).\n\n          -  Known hypersensitivity to any of the test materials or related compounds.\n\n          -  Known active use of recreational drug or alcohol dependence in the opinion of the\n             Investigator.\n\n          -  Any current use or use within 6 months prior to treatment start of medications which\n             are known to affect the metabolism and/or secretion of androgenic hormones:\n             ketoconazole, aminoglutethimide, oestrogens, progesterone, and anti-androgens.\n\n          -  Use of systemic or inhaled corticosteroids (topical application permitted).\n\n          -  Inability to give informed consent or to comply fully with the protocol."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656161", 
            "org_study_id": "Debio 8206-SC-301", 
            "secondary_id": "KRA75538"
        }, 
        "intervention": {
            "arm_group_label": "Triptorelin embonate 22.5 mg", 
            "description": "Two consecutive injections of triptorelin pamoate 22.5 mg at an interval of 24 weeks", 
            "intervention_name": "Triptorelin embonate 22.5 mg", 
            "intervention_type": "Drug", 
            "other_name": "Pamorelin"
        }, 
        "intervention_browse": {
            "mesh_term": "Triptorelin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2014", 
        "link": {
            "description": "Company website", 
            "url": "http://www.debiopharm.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Klerksdorp", 
                        "country": "South Africa", 
                        "state": "North West Province", 
                        "zip": "2571"
                    }, 
                    "name": "Wilmed Park Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7925"
                    }, 
                    "name": "New Grootte Schuur Hospital, Division of Urology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7130"
                    }, 
                    "name": "Vergelegen Medi-Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7505"
                    }, 
                    "name": "Department of Urology, Tygerberg Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7646"
                    }, 
                    "name": "Paarl Medical Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eastern Cape", 
                        "country": "South Africa", 
                        "zip": "6530,"
                    }, 
                    "name": "Dr JCM Bahlmann"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gauteng", 
                        "country": "South Africa", 
                        "zip": "0002"
                    }, 
                    "name": "Clinical Trial Unit, Room 2-54, Prinshof Medical Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gauteng", 
                        "country": "South Africa", 
                        "zip": "1619"
                    }, 
                    "name": "Clinresco Centres (Pty) Ltd"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gauteng", 
                        "country": "South Africa", 
                        "zip": "0083"
                    }, 
                    "name": "Pretoria Urology Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "1475"
                    }, 
                    "name": "East Rand Urology Research Unit, Clinix Private Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicentre, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer", 
        "overall_official": [
            {
                "affiliation": "Debiopharm SA", 
                "last_name": "Eija Lundstrom, MD", 
                "role": "Study Director"
            }, 
            {
                "last_name": "Johann C. M. Bahlmann, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "New Grootte Schuur Hospital", 
                "last_name": "Richard Barnes, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Vergelegen Medi-Clinic", 
                "last_name": "MC Bigalke, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinresco Centres (Pty) Ltd", 
                "last_name": "TJ Botha, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pretoria Urology Hospital", 
                "last_name": "Lance Coetzee, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "East Rand Urology Research Unit, Clinix Private Clinic", 
                "last_name": "T. Madlala, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinical Trial Unit, Room 2-54, Prinshof Medical Campus", 
                "last_name": "E Moshokoa, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Urology, Tygerberg Hospital", 
                "last_name": "SG Smit, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Paarl Medical Centre", 
                "last_name": "E Strasheim, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Suite 207, Wilmed Park Hospital", 
                "last_name": "Cle Van Der Walt, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Percentage of patients achieving castrate levels of serum testosterone (< 1.735 nmol/L) by Day 29.\nPercentage of patients maintaining castrate levels of serum testosterone (< 1.735 nmol/L) from Month 2 (Day 57) to end of Month 12 (Day 337).", 
            "measure": "Primary Efficacy", 
            "safety_issue": "No", 
            "time_frame": "Month 1 (Day 29) and from Month 2 (Day 57) to end of Month 12 (Day 337)"
        }, 
        "reference": [
            {
                "PMID": "10407987", 
                "citation": "Klippel KF, Winkler CJ, Jocham D, R\u00fcbben H, M\u00f6ser B, Gulati A. [Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma]. Urologe A. 1999 May;38(3):270-5. German."
            }, 
            {
                "PMID": "17096678", 
                "citation": "Torn\u00f8e CW, Agers\u00f8 H, Senderovitz T, Nielsen HA, Madsen H, Karlsson MO, Jonsson EN. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues. Br J Clin Pharmacol. 2007 Jun;63(6):648-64. Epub 2006 Nov 10."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656161"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary Efficacy\nProportion of patients showing \u2264 1.0 IU/L increase in serum LH from 0 hour to 2 hours post-injection of first and second IMP injection.\nPercentage changes in PSA from baseline throughout treatment.\nPercentage of patients who show testosterone levels \u2265 1.735 nmol/L after the second injection (AOC).\nPK/PD (subset of 15 patients)\nTestosterone PD metrics in subset of 15 patients: AUC1-169d, Cmax, tmax, tcast.\nTriptorelin PK metrics in subset of 15 patients (for both injection periods): AUC1-169d, AUC169-337d, Cmax, tmax.", 
            "measure": "Secondary efficacy", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 to Day 337"
        }, 
        "source": "Debiopharm International SA", 
        "sponsors": {
            "collaborator": {
                "agency": "Quintiles", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Debiopharm International SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}